Long-Term Results of Busulfan Plus High-Dose Idarubicin as a Conditioning Regimen to Autologous Stem Cell Transplantation Following Cytarabine Consolidation in Young Patients with Favorable or Intermediate-Risk Acute Myeloid Leukemia.

Blood Lymphat Cancer · 2026 · PMC13381044 · PMID 42473602

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

For intermediate-risk patients, the ASCT group showed a trend toward superior DFS and OS compared with the chemotherapy group, suggesting potentially better survival outcomes.

also in 53,322 other papers

did not reach statistical significanceno p-value reported

However, differences in OS ( P =0.13) and DFS ( P =0.21) between the two groups did not reach statistical significance ( Figure 2C,E ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.